|
Beta Alethine in Treating Patients With Low-Grade Lymphoma Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified health advice, travels to or treatment by using a genuine physician. We are not physicians. Always consult your dr. on Beta Alethine in Treating Patients With Low-Grade Lymphoma conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Beta Alethine in Treating Patients With Low-Grade Lymphoma Clinical research trials and Beta Alethine in Treating Patients With Low-Grade Lymphoma health trials occur in hundreds of cities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new drugs. The propose of the studies / undertakings is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Beta Alethine in Treating Patients With Low-Grade Lymphoma. Beta Alethine in Treating Patients With Low-Grade Lymphoma Clinical Trials and other clinical trials permit volunteers to acquire medical treatment choices before they are available to the masses. Some times the test subjects obtain professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Beta Alethine in Treating Patients With Low-Grade Lymphoma clinical trial. Participants oftentimes recieve the most expert healthcare available for their Beta Alethine in Treating Patients With Low-Grade Lymphoma condition. Hazards are a reality, however, and can include extra or frequent physician visits, health risks (potentially life-endangering), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "B" Clinical Trials Conditions > Beta Alethine in Treating Patients With Low-Grade Lymphoma  Beta Alethine in Treating Patients With Low-Grade Lymphoma
Beta Alethine in Treating Patients With Low-Grade Lymphoma
For Condition: Lymphoma
Status: No longer recruiting
Sponsor(s): LifeTime Pharmaceuticals ,
Synopsis: RATIONALE: Biological therapies such as beta alethine use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase I/II trial to study the effectiveness of beta alethine in treating patients who have low-grade lymphoma.
Details: OBJECTIVES: I. Determine the antitumor effects of low-dose beta-alethine in patients with low grade B-cell lymphoma. II. Assess the effects of this regimen on delayed-type hypersensitivity in these patients. III. Assess the safety of this regimen in this patient population. PROTOCOL OUTLINE: This is an multicenter study. Patients receive low-dose beta-alethine subcutaneously once every 2 weeks for a total of 6 doses in the absence of unacceptable toxicity. Patients with no evidence of tumor progression may receive additional courses of therapy. Patients are followed for 2 weeks from the last dose or for a minimum of 30 days if they withdraw due to an adverse event. PROJECTED ACCRUAL: Approximately 13-37 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically confirmed low grade B-cell lymphoma; Measurable residual disease after maximal response to prior chemotherapy OR Indolent disease not yet requiring therapy - No congenital immunodeficiency associated lymphoma - No primary lymphoma of the brain - No active brain involvement or leptomeningeal disease [A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology.] --Prior/Concurrent Therapy-- - Biologic therapy: Prior bone marrow transplantation allowed; At least 4 weeks since prior immunotherapy or cytokines - Chemotherapy: See Disease Characteristics; Prior intensive chemotherapy with stem cell support allowed; At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas, mitomycin, or high dose carboplatin) - Endocrine therapy: No concurrent corticosteroids - Radiotherapy: At least 4 weeks since prior radiotherapy to more than 25% of bone marrow - Surgery: Recovered from prior surgery; No prior solid organ transplantation - Other: No concurrent antiinflammatory agents including aspirin, or over the counter or prescription nonsteroidal antiinflammatory drugs; No concurrent immunosuppressive agents; No other concurrent investigational agents --Patient Characteristics-- - Age: 18 and over - Performance status: Karnofsky 50-100% - Life expectancy: At least 4 months - Hematopoietic: Neutrophil count at least 1,500/mm3; Platelet count at least 100,000/mm3; Hemoglobin at least 10 g/dL - Hepatic: Bilirubin less than 2.0 mg/dL; SGOT/SGPT no greater than 2.5 times upper limit of normal (ULN) (no greater than 5 times ULN if liver metastases present) - Renal: Creatinine no greater than 2.0 mg/dL; Calculated creatinine clearance at least 60 mL/min - Cardiovascular: No uncontrolled angina, heart failure, or arrhythmia; No acute changes on EKG - Other: Not pregnant or nursing; Fertile patients must use effective contraception; HIV negative; No AIDS Adequate nutritional status (total protein at least 60.0 g/L); No active bacterial infections (e.g., abscess or with fistula); No nonmalignant disease that would preclude study; No history of alcoholism, drug addiction, or psychotic disorders that would preclude study
Total Enrollment:
Location and Contact Information:
Overall Study Official:
SuzinMayerson, Study Chair, LifeTime Pharmaceuticals
Victory Over Cancer
Rockville, Maryland, 20852
United States
Additional Information:
Study ID Numbers: CDR0000068279; LIFETIME-LTP-99-02,LIFETIME-IRB-0300202,NCI-V00-1628
Study Start Date: August 2000
Record last reviewed: October 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00007839
Other Lymphoma Studies:
1. Sirolimus in Preventing Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
2. VNP40101M in Treating Patients With Advanced or Metastatic Cancer
3. Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss
4. Beta Alethine in Treating Patients With Low-Grade Lymphoma
5. Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma
Related Studies:
Other Lymphoma Clinical Trials
Other Maryland Clinical Trials
Other Rockville Clinical Trials
Beta Alethine in Treating Patients With Low-Grade Lymphoma
|
|
|
|
|
|
|
|
